Janus-I Science, Inc.
A small R&D company developing sample-to-answer diagnostic assays that integrate rapid specimen preparation, nanopore sequencing, and computational analytics for near-patient, field-forward, and high-throughput laboratory use. Focus areas include pathogen-agnostic identification, host-response biomarker assays for differential diagnosis, and automation of end-to-end workflows for healthcare and health-security customers.
Industries
N/A
Nr. of Employees
small (1-50)
Janus-I Science, Inc.
Products
Nanopore sequencing–based diagnostic assay (sample-to-answer)
A development-stage diagnostic assay that combines rapid specimen preparation, nanopore sequencing, and computational analytics to identify unknown viral and bacterial pathogens and report host-response biomarkers at or near the point of care.
Nanopore sequencing–based diagnostic assay (sample-to-answer)
A development-stage diagnostic assay that combines rapid specimen preparation, nanopore sequencing, and computational analytics to identify unknown viral and bacterial pathogens and report host-response biomarkers at or near the point of care.
Services
Design and integration of specimen preparation, sequencing, and analysis into automated workflows suitable for laboratory and near-patient use.
Development of algorithms and analytics to interpret nanopore sequence data, match microbes to reference databases, and report actionable clinical results.
Identification and quantitative assay development for mRNA host biomarkers to enable rapid differential diagnosis and triage.
Design and integration of specimen preparation, sequencing, and analysis into automated workflows suitable for laboratory and near-patient use.
Development of algorithms and analytics to interpret nanopore sequence data, match microbes to reference databases, and report actionable clinical results.
Identification and quantitative assay development for mRNA host biomarkers to enable rapid differential diagnosis and triage.
Expertise Areas
- Diagnostic assay development
- Nanopore sequencing applications
- Sample preparation and nucleic acid extraction
- Computational genomics and bioinformatics
Key Technologies
- Nanopore sequencing
- Rapid nucleic acid extraction
- Machine learning for biomarker classification
- RNA/DNA library preparation
News & Updates
Announcement of a DRIVe partnership to develop a diagnostic assay that identifies unknown viral pathogens in patient specimens using a sample-to-answer nanopore sequencing workflow.
Notice describing BARDA-funded work to develop a nanopore sequencing-based platform for pathogen identification and host-response detection in clinical specimens.
DRIVe contributed $710,619 toward a nanopore sequencing-based diagnostic assay development project estimated at $1,015,179 total cost.
Announcement of a DRIVe partnership to develop a diagnostic assay that identifies unknown viral pathogens in patient specimens using a sample-to-answer nanopore sequencing workflow.
Notice describing BARDA-funded work to develop a nanopore sequencing-based platform for pathogen identification and host-response detection in clinical specimens.
DRIVe contributed $710,619 toward a nanopore sequencing-based diagnostic assay development project estimated at $1,015,179 total cost.